QNCX insider trading
NasdaqGS HealthcareQuince Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Company website: www.quincetx.com
QNCX insider activity at a glance
FilingIQ has scored 61 insider transactions for QNCX since Sep 6, 2022. The most recent filing in our index is dated May 18, 2026.
Across the full history, 28 open-market purchases
and 2 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on QNCX insider trades is 57.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest QNCX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for QNCX?
- FilingIQ tracks 61 Form 4 insider transactions for QNCX (Quince Therapeutics, Inc.), covering filings from Sep 6, 2022 onwards. 9 of those were filed in the last 90 days.
- Are QNCX insiders net buyers or net sellers?
- Across the full Form 4 history for QNCX, 28 transactions (46%) were open-market purchases and 2 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does QNCX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is QNCX in?
- Quince Therapeutics, Inc. (QNCX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.38M.
Methodology & sources
Every QNCX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.